Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus UROPLUS SS.
SULTEN-10 vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic